Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04748796
Other study ID # PI2020_843_0057
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 1, 2021
Est. completion date March 2024

Study information

Verified date February 2023
Source Centre Hospitalier Universitaire, Amiens
Contact Slama Michel, Pr
Phone 03 22 08 78 41
Email slama.michel@chu-amiens.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Several data emphasize the relation between tachycardia (>90/min) and high mortality during septic shock. The investigators previously demonstrated the high mortality associated with hypercontractility, tachycardia and the presence of a left ventricular obstruction. A severe hypovolemia, a hyper adrenergic stimulation or a severe vasoplegia can all explain this relation between tachycardia, hypercontractility and the mortality during septic shock. Landiolol is another short-term acting beta-blocker with a half-life of 4 minutes without any beta 2 activity or membrane stabilizing effect. The landiolol has been used in critically ill patients to control supraventricular tachycardia but not in this context of tachycardia and septic shock. The investigators hypothesize that landiolol by reducing the heart rate may improve the survival of patients treated for a septic shock and presenting with an hypercontractility state.


Recruitment information / eligibility

Status Recruiting
Enrollment 360
Est. completion date March 2024
Est. primary completion date February 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years old - Patient admitted for a septic shock (according to the SEPSIS3 definition: sepsis with persisting hypotension (MAP<65mmHg or SAP <90mmHg) requiring vasopressors to maintain MAP>65mmHg and having a serum lactate level >2 mmol/L - Patient who received at least 30ml/kg of fluid and absence of fluid responsiveness - Left ventricular ejection fraction >65% (visual or Simpson method using echocardiography) - Tachycardia >100 bpm in sinus rhythm with a MAP 65mmHg for more than 1 hour - Patient receiving invasive mechanical ventilation - Patients adapted to the ventilator under sedation and analgesia - Written informed consent - Patient covered by French national health insurance Exclusion Criteria: - Patients with inclusion criteria already present for more than 36 hours - Patient treated with Dobutamine, adrenaline or isoprenaline - Patient currently treated with beta blockers (previous home betablocker treatment is not an exclusion criteria) - Supra ventricular (atrial fibrillation or flutter) or ventricular arrhythmias - Patients with any form of cardiac pacing - Sick sinus syndrome - Severe atrioventricular (AV) nodal conductance disorders (without pacemaker): 2nd or 3rd degree AV block - Known pulmonary hypertension - ScVO2 <70% - Moribund - Cardiac arrest - Non-treated phaeochromocytoma - Acute asthmatic attack - Pregnant or breastfeeding woman - Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision), - Age <18 years - Hypersensitivity to the active substance or to any of the excipients - Severe bradycardia (less than 50 beats per minute) - Cardiogenic shock - Severe hypotension - Decompensated heart failure when considered not related to the arrhythmia - Severe, uncorrectable metabolic acidosis - Presence of significant bleeding, or - Acute respiratory distress defined by increased oxygen dependency, polypnea > 30 /min, signs of struggle (pulling, thoraco-abdominal sway) if the patient is not intubated and ventilated.

Study Design


Intervention

Other:
echocardiography
Full echocardiography will be performed at baseline and during the follow-up at H1, H3, H6 and H12.
Drug:
Landiolol
Patients randomized to the experimental group will be treated according to the standard of care plus for 2 days with landiolol IV started at a dose of 1 microgram/kg/min and progressively increased every 10 minutes to a maximum of 40 micrograms/kg/min.

Locations

Country Name City State
France CHU Amiens Amiens

Sponsors (28)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire, Amiens Centre Hospitalier Arras, Centre Hospitalier de Beauvais, Centre Hospitalier de Bethune, Centre Hospitalier de Lens, Centre Hospitalier de Roubaix, Centre Hospitalier Universitaire de Nimes, Centre Hospitalier VALENCIENNES, CH Calais, CH Cherbourg, CH Compiègne, CH Dieppe, CH Douai, CH Elbeuf, CH Laon, CH Le Havre, CH Lomme, CH Montreuil, Groupe Hospitalier Pitié-Salpêtrière, Henri Mondor University Hospital, Hôpital Edouard Herriot, Hospital Ambroise Paré Paris, Hospital Avicenne, Tourcoing Hospital, University Hospital, Brest, University Hospital, Caen, University Hospital, Lille, University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Variation of mortality rate in landiolol group compared to control group day 28
See also
  Status Clinical Trial Phase
Recruiting NCT03649633 - Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock Phase 1/Phase 2
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Completed NCT05629780 - Temporal Changes of Lactate in CLASSIC Patients N/A
Recruiting NCT04796636 - High-dose Intravenous Vitamin C in Patients With Septic Shock Phase 1
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Recruiting NCT05066256 - LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Recruiting NCT02676427 - Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
Recruiting NCT02580240 - Administration of Hydrocortisone for the Treatment of Septic Shock N/A
Recruiting NCT02565251 - Volemic Resuscitation in Sepsis and Septic Shock N/A
Completed NCT02638545 - Hemodynamic Effects of Dexmedetomidine in Septic Shock Phase 3
Terminated NCT02335723 - ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber N/A
Not yet recruiting NCT02547467 - TOADS Study: TO Assess Death From Septic Shock. N/A
Completed NCT02079402 - Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Phase 4
Completed NCT02204852 - Co-administration of Iloprost and Eptifibatide in Septic Shock Patients Phase 2